| 2.53 0.08 (3.27%) | 09-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.16 | 1-year : | 3.44 |
| Resists | First : | 2.7 | Second : | 2.95 |
| Pivot price | 2.49 |
|||
| Supports | First : | 2.3 | Second : | 1.92 |
| MAs | MA(5) : | 2.47 |
MA(20) : | 2.49  |
| MA(100) : | 2.8 |
MA(250) : | 3.42 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 41.2 |
D(3) : | 38 |
| RSI | RSI(14): 48.5 |
|||
| 52-week | High : | 8.53 | Low : | 2.28 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ GNLX ] has closed below upper band by 35.6%. Bollinger Bands are 33.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.55 - 2.57 | 2.57 - 2.58 |
| Low: | 2.43 - 2.45 | 2.45 - 2.47 |
| Close: | 2.5 - 2.53 | 2.53 - 2.55 |
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.
Fri, 18 Sep 2026
Genelux Corporation Common Stock (NASDAQ: GNLX) Stock Price, News & Analysis - Kalkine
Fri, 04 Sep 2026
Have Genelux Insiders Been Selling Stock? - simplywall.st
Wed, 02 Sep 2026
Genelux CEO Zindrick sells $91,899 in common stock - Investing.com
Wed, 02 Sep 2026
Genelux CTO Joseph Cappello sells $28,112 in company stock - Investing.com
Thu, 13 Aug 2026
Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates - GlobeNewswire
Fri, 31 Jul 2026
GNLX Q1 2026 Earnings: Wider-Than-Expected Loss and 3.6% Share Decline as Clinical Pipeline Takes Center Stage - careplusvn.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 45 (M) |
| Held by Insiders | 3.644e+007 (%) |
| Held by Institutions | 12.8 (%) |
| Shares Short | 3,110 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.628e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -455 % |
| Return on Assets (ttm) | 275 % |
| Return on Equity (ttm) | -77.9 % |
| Qtrly Rev. Growth | 8000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -317.74 |
| EBITDA (p.s.) | 14285.7 |
| Qtrly Earnings Growth | -0.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -25 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 3.93 |
| Dividend | 0 |
| Forward Dividend | 3.52e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|